1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, H1 2013

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE). Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).
- A review of the Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) 7
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics - Products under Development by Companies 12
Companies Involved in Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics Development 13
Amgen Inc. 13
Rigel Pharmaceuticals, Inc. 14
Celgene Corporation 15
Astion Pharma A/S 16
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
AMG-811 - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
CC-11050 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
levalbuterol sulfate - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
R-333 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics - Drug Profile Updates 27
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics - Dormant Products 28
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Product Development Milestones 29
Featured News and Press Releases 29
Sep 05, 2012: Rigel Pharma Initiates Phase II Clinical Study With R333 For Discoid Lupus 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables


Number of Products Under Development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), H1 2013 7
Products under Development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Mid Clinical Stage Development, H1 2013 10
Comparative Analysis by Early Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Amgen Inc., H1 2013 13
Rigel Pharmaceuticals, Inc., H1 2013 14
Celgene Corporation, H1 2013 15
Astion Pharma A/S, H1 2013 16
Assessment by Monotherapy Products, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 21
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics - Drug Profile Updates 27
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics - Dormant Products 28

List of Figures


Number of Products under Development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), H1 2013 7
Products under Development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Mid Clinical Stage Products, H1 2013 10
Early Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 17
Assessment by Route of Administration, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Molecule Type, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Acyl CoA Desaturase ...

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histamine H4 Recepto ...

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.